Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine plus Docetaxel vs Ifosfamide in Relapsed Osteosarcoma
NCT02718482Phase 2Terminated
- Sponsor
- Italian Sarcoma Group
- Start
- Apr 2016
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, docetaxel in osteosarcoma (OS), sponsored by Italian Sarcoma Group. Started Apr 2016; status: terminated.
02
Drugs
gemcitabinedocetaxel
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT02718482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02718482.